儿童肿瘤正电子发射断层扫描(PET)/计算机断层扫描(CT)中白色脂肪组织的18F-2-氟-2-脱氧葡萄糖摄取
研究回顾性分析了2年内689例患儿共1361次肿瘤FDG PET/CT,白色脂肪FDG摄取发生率为0.6%(9/1361),表现为皮下脂肪(特别是颊部、体壁和臀部)摄取增高伴血池和肝脏放射性分布减少,全部发生于诱导后且均在使用糖皮质激素,停药后随访恢复。
要点
- 儿童肿瘤诱导后PET/CT若见皮下白色脂肪(颊部、体壁、臀部)FDG摄取增高伴血池和肝脏摄取相对减低,应想到糖皮质激素相关分布改变。
- 该表现罕见(9/1361次,0.6%),仅见于诱导后扫描,全部患儿当时在使用糖皮质激素。
- 此分布改变可与棕色脂肪摄取鉴别,停药后随访PET/CT显示恢复。
关键影像表现/征象
- 皮下脂肪FDG摄取增高,尤其见于颊部、体壁和臀部区域,伴放射性示踪剂从血池和肝脏转移。
- 外周白色脂肪摄取增高程度从显著到轻微不等,分布模式与棕色脂肪组织不同。
- 这些表现仅见于诱导后PET/CT,随访PET/CT显示停用糖皮质激素后该效应消退。
诊断标准与关键数值
- 白色脂肪FDG摄取发生率:9/1361次(0.6%)儿童肿瘤PET扫描。
- 所有出现该分布改变的患儿均在癌症诱导治疗中接受糖皮质激素,且仅在诱导后PET/CT上识别。
临床应用与阅片要点
- 阅片时注意识别皮下白色脂肪(颊部、体壁、臀部)FDG摄取增高伴血池和肝脏摄取相对减低的模式,并与棕色脂肪分布鉴别。
- 报告时应考虑该分布改变可能限制PET扫描的诊断质量并干扰治疗反应评估,结合患儿糖皮质激素使用情况和扫描时机(诱导后)进行判断。
- 随访PET/CT可记录停用糖皮质激素后该效应的消退。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Altered biodistribution of [F-18]2-fluoro-2-deoxyglucose (FDG) is sometimes encountered in pediatric patients undergoing chemotherapy for lymphoma on post-induction positron emission tomography (PET) imaging. A characteristic pattern of increased FDG uptake in white adipose tissue can be seen, particularly in the buccal regions, body wall and gluteal regions, with a shift of radiotracer away from the blood pool and liver. This altered biodistribution has been attributed to effects of corticosteroids in pediatric and adult patients and is important to recognize because of its potential for limiting the diagnostic quality of the PET scan and interfering with therapeutic response assessment.
OBJECTIVE: In contrast to the well-known metabolically active brown fat seen on up to one-third of pediatric PET scans, white fat is usually non-metabolically active. We sought to determine the incidence of altered distribution of FDG in subcutaneous white adipose tissue in pediatric patients undergoing PET imaging and to assess the association with corticosteroid use.
MATERIALS AND METHODS: We reviewed the medical records and imaging for four children in whom altered biodistribution in white adipose tissue was present on post-induction FDG PET/CT, identified during routine clinical practice. All four were receiving corticosteroids as part of their chemotherapy. We then retrospectively reviewed oncology FDG PET/CT scans over a 2-year period (1,361 scans in 689 patients) to determine the incidence of uptake in white fat by qualitative visual assessment. In the children identified with altered biodistribution, we measured maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean) in areas of subcutaneous white fat, the buccal regions, body wall or gluteal soft-tissue regions, liver and blood pool. We reviewed all medical records, including medication lists. We summarize the relevant clinical and imaging findings of 13 pediatric patients, including the 4 index patients.
RESULTS: We determined the incidence of FDG uptake in white fat to be rare, found in 9 of 1,361 (0.6%) PET scans performed for pediatric cancer evaluation. FDG uptake was increased in subcutaneous adipose tissue, particularly in the buccal regions, body wall and gluteal regions, with a shift of radiotracer away from the blood pool and liver. The degree of increased uptake in peripheral white fat varied from marked to mild, and the biodistribution was distinct from that of brown adipose tissue. Children with this altered biodistribution were uniformly receiving corticosteroids as part of induction treatment for their cancer, and these findings were only identified on post-induction PET/CT. Follow-up PET/CT documented resolution of this effect after treatment with corticosteroids ceased.
CONCLUSION: Our findings support the current understanding that characteristic uptake of FDG in white adipose tissue is mediated by corticosteroid effect. Although this altered biodistribution is rare (<1% of PET scans) it could impair the diagnostic quality of the scan, affecting image interpretation, and should be recognized when present.
引用
- Wong KK, Sedig LK, Bloom DA, et al. 18F-2-fluoro-2-deoxyglucose uptake in white adipose tissue on pediatric oncologic positron emission tomography (PET)/computed tomography (CT). Pediatr Radiol. 2019. PMID: 31776602. doi:10.1007/s00247-019-04574-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。